What Genes Affect Glutathione Production? Your Genetic Guide

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on longevity and healthy aging. Browse all Longevity & Telomeres education

Glutathione is the body's master antioxidant — present in virtually every cell, consuming more biosynthetic energy than any other small molecule antioxidant, and protecting against oxidative damage, toxic chemical conjugation, and the pro-inflammatory lipid peroxidation cascade that underlies accelerated aging. Its concentration is not uniform across individuals. Intracellular glutathione levels are substantially determined by genetics — by the activity of the enzymes that synthesize it, the enzymes that recycle its oxidized form back to the reduced form, the enzymes that deploy it for detoxification, and the transcription factor that governs the entire antioxidant gene expression program. The PlexusDx Precision Peptide Genetic Test maps glutathione pathway genetics as part of 14 pathways, 49 peptides, and 150+ genetic insights, turning the abstract question "do I have enough glutathione?" into a specific answer rooted in your individual biological architecture.

Glutathione Biology: Synthesis, Recycling, and Deployment

Glutathione (γ-L-glutamyl-L-cysteinyl-glycine, or GSH) is a tripeptide synthesized in two ATP-requiring enzymatic steps that together define the production capacity of the glutathione system:

Step 1 — Glutamate + Cysteine → γ-Glutamylcysteine. This rate-limiting step is catalyzed by glutamate-cysteine ligase (GCL) — a heterodimeric enzyme composed of a catalytic subunit encoded by GCLC and a modifier subunit encoded by GCLM. GCLC carries the active site and determines baseline enzyme activity; GCLM increases GCLC's catalytic efficiency and lowers its inhibition by GSH (the product). The GCLC/GCLM holoenzyme is inhibited by its own product — making the GSH/γ-GluCys ratio a direct feedback signal regulating synthesis rate. GCLC and GCLM genetic variants are therefore the primary genetic determinants of glutathione synthetic capacity.

Step 2 — γ-Glutamylcysteine + Glycine → Glutathione. Catalyzed by glutathione synthetase (GSS), this step is generally not rate-limiting under normal conditions — but GSS variants that reduce enzyme activity can become limiting when step 1 is driving high γ-GluCys throughput, or when glycine availability is restricted.

Recycling — GSSG → GSH. GSH is oxidized to GSSG (glutathione disulfide) when it neutralizes reactive oxygen species or conjugates electrophiles. Glutathione reductase (GSR) recycles GSSG back to GSH using NADPH as the electron donor. GSR activity is essential for maintaining the GSH/GSSG ratio — the primary measure of cellular redox status. GSR genetic variants that reduce enzyme activity lower the recycling efficiency of the glutathione system — reducing the GSH/GSSG ratio even when synthesis rate is adequate.

Deployment — GPX and GST families. Reduced GSH is deployed through two enzyme families: glutathione peroxidases (GPX1-8) that use GSH to neutralize hydrogen peroxide and lipid hydroperoxides (producing GSSG), and glutathione S-transferases (GSTM1, GSTT1, GSTP1) that conjugate electrophilic xenobiotics and endogenous reactive species to GSH for excretion. GPX and GST activity determines the rate at which GSH is consumed in antioxidant and detoxification reactions — and therefore the demand placed on GCLC/GCLM synthesis and GSR recycling to maintain GSH pools.

GCLC: The Rate-Limiting Genetic Switch

GCLC (glutamate-cysteine ligase, catalytic subunit) encodes the enzyme that executes the rate-limiting first step of glutathione synthesis. GCLC genetic variation shapes glutathione synthetic capacity through two primary mechanisms:

The GAG trinucleotide repeat polymorphism. A trinucleotide repeat (GAG)n polymorphism in GCLC intron 9 — with common alleles of 7, 8, and 9 repeats — is associated with variation in GCLC expression and erythrocyte glutathione levels. The 7-repeat allele (GCLC*7) is associated with lower GCLC expression and lower erythrocyte GSH in published studies, while 9-repeat carriers show higher erythrocyte GSH concentrations. This repeat variant is one of the most directly relevant GCLC genetic determinants of baseline glutathione production capacity.

rs17883901 (c.-129C/T promoter variant). Located in the GCLC promoter, this variant affects transcriptional activity and has been associated with altered GCLC expression in endothelial and hepatic cells. Reduced GCLC promoter activity from this variant produces a lower basal GCLC enzyme pool — constraining the rate of γ-GluCys synthesis from the transcriptional level, upstream of any allosteric or substrate-availability-related regulation.

GCLC activity is also influenced by NFE2L2 (NRF2)-mediated transcriptional regulation — making GCLC expression responsive to the cellular oxidative state through the antioxidant response element (ARE) in the GCLC promoter. This NRF2 × GCLC interaction means that NFE2L2 genetic variants that reduce NRF2 activity compound GCLC promoter variant effects — reducing both baseline expression and stress-induced GCLC upregulation simultaneously.

GCLM: The Modifier Subunit That Amplifies Synthesis Efficiency

GCLM (glutamate-cysteine ligase, modifier subunit) does not carry catalytic activity but substantially amplifies GCLC's function — increasing the holoenzyme's Vmax approximately two-fold and reducing the Ki for GSH feedback inhibition approximately ten-fold. In practical terms: GCLM determines how efficiently GCLC operates at physiological GSH concentrations and how readily the synthesis rate increases in response to GSH depletion.

The most studied GCLM variant in functional glutathione research is rs41303970 (-588C/T) — a promoter polymorphism that reduces GCLM transcription. T allele carriers produce less GCLM mRNA → less GCLM protein → lower GCLC/GCLM holoenzyme efficiency → lower γ-GluCys synthesis rate at equivalent GCLC levels. The GCLM -588T allele has been associated in published studies with lower plasma cysteine levels and reduced lymphocyte GSH concentrations in healthy adults.

The GCLC × GCLM compound genotype is the most informative genetic picture of glutathione synthetic capacity: high GCLC expression with low GCLM efficiency produces a catalyst-rich but inefficient enzyme; low GCLC expression with high GCLM efficiency produces an efficient but quantity-limited enzyme. The lowest-capacity combination — low GCLC promoter activity plus GCLM -588T — produces reduced synthesis at both the quantity and efficiency levels simultaneously.

GPX1: The Primary Glutathione Peroxidase and Its Pro198Leu Variant

GPX1 (glutathione peroxidase 1) is the most abundant and ubiquitously expressed member of the GPX family — the primary cytoplasmic and mitochondrial enzyme using GSH to reduce hydrogen peroxide (generated by SOD1/SOD2 superoxide dismutation) and small organic hydroperoxides to water and alcohol, respectively. GPX1 activity determines how efficiently hydrogen peroxide is cleared before it can participate in Fenton chemistry to generate the highly reactive hydroxyl radical — the most damaging ROS in the cellular environment.

The most clinically significant GPX1 variant is Pro198Leu (rs1050450) — a C→T transversion in codon 198 that substitutes leucine for proline in the GPX1 protein. The Leu198 (T) allele is associated with reduced GPX1 catalytic efficiency in published biochemical and epidemiological studies, with Leu/Leu homozygotes showing approximately 30–40% lower GPX1 activity than Pro/Pro homozygotes in some tissue and cell line systems. In biological aging terms: reduced GPX1 activity means slower hydrogen peroxide clearance → higher steady-state H₂O₂ → greater Fenton-derived hydroxyl radical production → more oxidative DNA damage → more PARP1 NAD+ consumption → lower NAD+ → lower SIRT1 deacetylase activity. The GPX1 × SOD2 × PARP1 × SIRT1 cascade is one of the clearest mechanistic chains connecting antioxidant genetics to NAD+ depletion and the broader aging program.

GPX1 also requires dietary selenium for its active site selenocysteine — meaning GPX1 genetic capacity is only fully realized when selenium nutritional status is adequate. Selenium deficiency phenocopies GPX1 loss-of-function: both reduce GPX1 activity and impair hydrogen peroxide clearance. The interaction between GPX1 genotype and selenium status is clinically relevant for individuals with Leu/Leu GPX1 who are also nutritionally selenium-insufficient — compounding the functional GPX1 deficit from two independent directions.

GSTM1 and GSTT1: The Glutathione Conjugation Null Deletions

The GSTM1 (glutathione S-transferase Mu 1) and GSTT1 (glutathione S-transferase Theta 1) genes undergo complete homozygous deletion in a substantial fraction of the population — eliminating the encoded enzyme activity entirely. GSTM1 null deletion is present in approximately 50% of European-ancestry populations; GSTT1 null deletion in approximately 20%. These are not rare variants — they are common population polymorphisms with direct functional consequences for the detoxification arm of the glutathione system.

GSTM1 null (absence of Mu-class GST activity) eliminates the conjugation of electrophilic metabolites — including reactive metabolites of polycyclic aromatic hydrocarbons, aflatoxins, and epoxide-bearing compounds — to glutathione for mercapturic acid pathway excretion. GSTM1 null individuals metabolize these electrophilic compounds more slowly and accumulate more covalent DNA adducts from environmental exposures than GSTM1-present individuals. GSTM1 null status is also associated with reduced recycling of some oxidized lipid species through the glutathione detoxification route — increasing lipid peroxidation product accumulation.

GSTT1 null (absence of Theta-class GST activity) eliminates detoxification of halogenated hydrocarbons, epoxides of dihalomethanes, and endogenous reactive species including ethylene oxide and propylene oxide. GSTT1-null individuals have reduced capacity to conjugate and excrete these compounds — increasing their intracellular residence time and reactivity with DNA and protein.

Critically: GSTM1 and GSTT1 null genotypes increase demand on the glutathione synthesis system without increasing synthetic output. When detoxification demands are high — from dietary exposures, environmental toxicants, or high metabolic oxidative output — null individuals deplete GSH pools faster than GSTM1/GSTT1-present individuals under equivalent conditions. The combination of null GSTM1 + null GSTT1 + low-activity GCLC synthesis genetics represents the most GSH-depleted compound genotype in the population.

GSR: The Recycling Engine

GSR (glutathione reductase) catalyzes the NADPH-dependent reduction of GSSG back to two molecules of GSH — the recycling step that sustains the GSH pool without requiring de novo synthesis from amino acids. GSR activity is the primary determinant of the GSH/GSSG ratio at equivalent synthesis rates, and the GSH/GSSG ratio is the most sensitive biochemical indicator of cellular redox status.

GSR variants that reduce enzyme activity or stability compromise recycling efficiency — increasing the fraction of glutathione trapped as GSSG rather than available as reduced GSH for antioxidant and detoxification reactions. GSR activity is also NADPH-dependent, connecting glutathione recycling to the pentose phosphate pathway (G6PD activity) and the NADPH-generating capacity of the cell. G6PD deficiency — which reduces NADPH production — phenocopies GSR impairment for exactly this reason: less NADPH means less GSR-driven GSSG reduction, less available GSH, and more oxidative stress under equivalent ROS production.

NFE2L2 (NRF2): The Master Transcriptional Regulator

Every gene discussed above — GCLC, GCLM, GSR, GPX1, GSTM1, GSTT1 — has antioxidant response element (ARE) sequences in its promoter that are activated by the transcription factor NRF2, encoded by NFE2L2. NRF2 is the master switch of the cellular antioxidant response: when oxidative stress is sensed, KEAP1 (the NRF2 repressor) is oxidized at critical cysteine residues, releasing NRF2 for nuclear translocation and ARE-driven upregulation of the complete antioxidant gene set — including GCLC, GCLM, GSR, GPX1, GSTP1, and the thioredoxin system.

NFE2L2 promoter variants — particularly the -617C/A, -651G/A, and -653A/G haplotypes that reduce NRF2 transcription — produce a transcription factor that is present in lower amounts before stress and therefore generates a smaller ARE-driven gene expression response when oxidative stress is sensed. Individuals with low-activity NFE2L2 promoter haplotypes have lower basal GCLC, GCLM, and GSR expression — and mount a blunted antioxidant gene induction response to oxidative challenge. This NFE2L2 genetic baseline is the transcriptional layer above all the individual enzyme variants described above: it sets the stress-responsive amplification capacity of the entire glutathione synthesis, recycling, and deployment network.

The connection to FOXO3 is direct and functionally significant: both FOXO3 and NRF2 independently activate GCLC, GCLM, and GPX1 expression through separate transcriptional pathways — FOXO3 through forkhead response elements (FHREs) and NRF2 through AREs. High-activity FOXO3 × high-activity NFE2L2 compound genotypes produce the most robustly supported glutathione system, both at baseline and under stress-induced upregulation. Low-activity FOXO3 × low-activity NFE2L2 represents the most transcriptionally limited glutathione support architecture. Full FOXO3 context: Does FOXO3 Affect How You Age?

The Transsulfuration Connection: MTHFR, Cysteine, and Glutathione Substrate

Glutathione synthesis requires cysteine as its limiting amino acid substrate — not methionine directly, but the cysteine produced from methionine through the transsulfuration pathway (methionine → SAH → homocysteine → cystathionine → cysteine, catalyzed by CBS and CTH). This means that any genetic or nutritional impairment that reduces methionine availability or transsulfuration pathway efficiency reduces the cysteine pool available to GCLC for glutathione synthesis.

MTHFR C677T connects to glutathione through two mechanisms: first, impaired MTHFR function reduces 5-MTHF availability for methionine synthase, potentially reducing methionine regeneration from homocysteine and impairing the methionine → cysteine transsulfuration supply; second, elevated homocysteine from MTHFR impairment directly depletes GSH by forming mixed disulfides (homocysteine-glutathione) that reduce available GSH without consuming it through peroxidase reactions. This MTHFR × glutathione interaction makes MTHFR genotype relevant to glutathione status even though MTHFR is a methylation cycle gene rather than a glutathione pathway gene — a cross-pathway dependency that isolated single-gene testing misses entirely. Full methylation context: Methylation and Longevity: How MTHFR Shapes Your Aging Pathway.

The complete longevity panel picture — how glutathione genetics connects to SOD2, FOXO3, SIRT1, NAD+, and MTHFR as an integrated antioxidant and aging network — is in the Complete Guide to Genetic Longevity Testing.

The Precision Peptide Genetic Test analyzes how your genes influence longevity and aging pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to map your glutathione production genetics across the complete longevity panel? Take the Precision Peptide Genetic Test

Frequently Asked Questions About Glutathione Genetics

Which gene most directly controls how much glutathione your body makes?

GCLC encodes the rate-limiting enzyme in glutathione synthesis — glutamate-cysteine ligase catalytic subunit. GCLC variants including the GAG repeat polymorphism and rs17883901 promoter variant alter enzyme expression and production capacity. GCLM amplifies GCLC efficiency. The Precision Peptide Genetic Test maps both within 14 pathways and 150+ genetic insights alongside NFE2L2, GPX1, and GSTM1.

What does GSTM1 null mean for my glutathione status?

GSTM1 null deletion eliminates Mu-class glutathione S-transferase activity — the enzyme conjugating electrophilic metabolites to GSH for excretion. Null individuals (~50% of European populations) deplete GSH faster under oxidative exposure. Combined with low GCLC expression, GSTM1 null produces the most depleted compound genotype. The Precision Peptide Genetic Test maps GSTM1 within 14 pathways, 150+ insights.

How does MTHFR affect glutathione levels?

MTHFR C677T impairment reduces methionine cycle efficiency, potentially lowering cysteine availability through transsulfuration — the pathway supplying the limiting amino acid substrate for GCLC-mediated synthesis. Elevated homocysteine also depletes GSH through mixed disulfide formation. The Precision Peptide Genetic Test maps MTHFR alongside GCLC, GCLM, and GPX1 within 14 pathways, 150+ genetic insights.

This article is part of the PlexusDx Education Hub. Browse all Longevity & Telomeres education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.